Acology Inc (OTCMKTS:ACOL) Releases Letter To Shareholders

Acology Inc (OTCMKTS:ACOL) filed its 10-Q, which displays firm’s continued strength and health. The company has lessened its advertising and operational costs while continuing to advance. Net profits have surged YoY and the remarkable growth in first quarter continues unchanged. This year is expected to establish new records for profitability.

The debt continues to lessen and no new debt have been obtained and none are contemplated. New product sales now comprise for 25% of total revenue and are increasing month to month.

The update

Curt Fairbrother, the CEO of Acology, reported that in answer to the different inquiries that they have received from their stockholders about their plans for improving international and national marketing profile, they are now assured that they can extend spending and continue to enhance overall international position. In addition, the revenue pace continues to surpass their expectations, the production capacity continues to handle growth and the inventory levels are good.

Acquisition discussions with EZ Health Solutions, comprising the ownership of intellectual resources, continues and their preparations to establish a new CBD-Infused Health Products segment has gained momentum. Acology CEO reported that there has been remarkable interest in the industry about their strategies to expand. They are extremely excited about their current situation and positive about the imminent period.

Acology has recorded considerable success with its endeavors and have sustained as it continued to develop and evolve. Fairbrother expressed his gratitude for shareholders’ constant confidence and support. Sales or investors information can be accessed on company’s site or by phone.

The production and distribution facility is based in California. Acology is listed on the OTC marketplace under the ticker ACOL. The company has different online sites for its businesses of the hospice and palliative care market, as well as for the medical and recreational marijuana industry. Orders for products can be placed online or by phone.


Acology Inc (OTCMKTS:ACOL) Reports Big First Quarter

Acology Inc (OTCMKTS:ACOL) CEO Curt Fairbrother reported that as a result of product additions later in year, and continued surges of their signature product, the company sales have considerably accelerated beyond their preliminary projections for Q1 2017. The company sold almost half as numerous products in Q1 2016. This is attributable to advantages in both global and national distribution, the adding of new distributors and growth in the Canadian market. They consider that these trends will advance and that 2017 will be an important year for them.

The details

Friday’s publication of their 10K tracks the consistent growth of their company from its start and the success they had in maintaining steadily high gross margins. By its nature the fiscal report is extremely conservative. It is worth mentioning that double-digit jumps in yearly sales have been extraordinarily consistent.

In the last three years, the company has noted their business grow by a remarkable 770%. The manufacturing unit is at less than 45% of total capacity and set for increased production. The debt is manageable and the prospect to remarkably reduce it has presented itself. They will update their progress in this attempt as it advances.

Acology has always prided on expanding the operations from the inside-out. The management had the foresight to interpret the emphasis and significance of multi-functional packaging in the recreational and medical cannabis industry.

Expanding their sales force was the result of their commitment to become an international presence, particularly in Canada. Most of the company’s revenue is invested back into business. The management remain committed to firm’s principles; continued product diversity, steady growth, concentrated person-to-person marketing and sales and the assurance of exceptional customer service.

Acology is confident that this year will be a breakout year for company. There are all indications, despite some ambiguity on the federal level, that the industry will continue to prosper and grow.


Acology Inc (OTCMKTS:ACOL) Expects To Capitalize On Upcoming Legislation In Canada

Acology Inc (OTCMKTS:ACOL) has outperformed investors’ expectations this year. The company strongly picked up in the midst of a growing wave of cannabis legalization towards the end of last year gaining more momentum in 2017.

The company has now announced that its multinational expansion program will be boosted following the planned legalizing of cannabis in Canada. The company said this following reports that Justin Trudeau, the Canadian Prime Minister is planning to ask for legalization in the coming few weeks. Currently, North America presents the highest growth opportunities for Acology.

According to the company, there is high possibility that the referendum will sail through and companies that have been waiting for this stand high chances to benefit from the new legislation. Acology noted that it has been doing business in Canada since 2013 and has heavily invested in expanding its business in the country. Additionally, the company has recorded an increase in its overall sales in Canada during the first quarter of 2017. It is also holding talks with several distributors in the country.

According to the company, the Canadian market is worthy approximately $10 billion for the first year. Consequently, the company has been working to expand its reach in the recreational and medical cannabis distribution network.  The company is of belief that the distribution points will boost that market reach that the company is anticipating for.

In an earlier statement, the company said it has presence in 19 countries. This is shown in the international sales in the past year which accounted for 20% of the company’s total sales. The company says it expects recent as well as planned sales drive to increase its sales by 15%. Consequently, the company is working to expand its production facility by 7,000 square feet in addition to working towards launching hydroponic products. Additionally, the company recently hired four more executives and plans to employ more to add on their networking experience.

Acology Inc closed the previous session at $0.0169 which represents 1.2% that the previous session. The total volume traded was 8.13 million for the trading session.

Science Technology

Acology Inc (OTCMKTS:ACOL) Reports Strong Earnings Despite Higher Expenses

Acology Inc (OTCMKTS:ACOL) posted that earnings had surged 12.5% throughout the last quarter of FY2016, despite notable expenses in expansion, infrastructure and additional manpower costs. Executives are estimating that the net-impact of investments done in the year to expand the business, will disburse dividends immediately.

Different investments comprise expansion of warehouse businesses in Canada and California, improving technology and printing capabilities and hiring additional staff to manage increased sales. Sales of all products increased considerably since the start of the new year and Acology continues to be confident that this style will continue for the near future.

The buzz

Acology management confidence has spilled-over to business partners and investors alike. The company’s sales and fulfillment subsidiary unit, D&C Distributors LLC, has announced that international orders for products have expanded well as compared to initial predictions. Partnership and investment proposals have also intensified, endorsed by the steady, sustained advancement of the firm and the international implications of a rapidly-surging recreational and medical cannabis industry.

Earlier, the company stated that the sales in January were record sales in its company history. In fact, it surpassed previous marks recorded during 4Q2016. Acology staff have expressed confidence that the 1Q2017 would advance this trend, laying their optimism on sustained expansion in Canada and the inclusion of new products and product lines. Income in the reported quarter surged 33% above the same quarter in 2016. Unit sales of all offerings, led by the MedTainer™, surged by 25% over last year.

The cannabis industry is continuing to embrace the multi-functional container as it continues to grow, prompting Acology and its subsidiary to increase production and match the demand. In addition, Boveda humidity packs are planted in each Medtainer even before shipping, brining increased value to the product and generating increased demand for Boveda products countrywide. The company commenced the year by approaching almost 4,000 distributors worldwide.

Marijuana Technology

Where Cannabis Science Inc (OTCMKTS:CBIS) Stands In The Legalized Cannabis Industry

The injection of modern know-how into the evolving world of legal medical marijuana and cannabis is helping the industry scale new heights and increase interaction with clients, mainly when it comes to cannabis subjects in the medical aspect of the industry. The interaction created between the explosive cannabis industry and modern technology is allowing pioneers in marijuana to leverage client technology engagement for firms such as Cannabis Science Inc (OTCMKTS:CBIS) and Acology Inc (OTCMKTS:ACOL).

The financials

For the first three quarters closed September 30, 2016, Cannabis Science posted revenue of $8,520 compared to revenue of $4,150 in the comparable period, a year earlier. This jump in revenue can be attributed to assets procurement of Equi-Pharm and license income from product sales. The R&D costs declined by $116,748 to $265,024 for the first three quarters closed September 2016 compared to $381,772 in the same period, a year earlier.

Loss on investment improved by $971,500 to $971,500 for the first three quarters closed September 30, 2016 against $0 for the same period a year earlier. Net loss on debt settlement dropped by $349,431 to over $4.138 million for the nine months closed September 30, 2016 against over $4.488 million for the nine months closed September 30, 2015. This drop is due to the lesser sum of debt settlement and reduced share price of the firm’s stock relative to loss pertaining to settling debt at a reduced share price.

G&A costs dropped by around $2.628 million to approximately $6.082 million for the nine months closed September 30, 2016 against $8.710 million for the nine months closed September 30, 2015.  This decline can be attributed to decreased stock compensation cost due to management consulting and bonus deals.

 The firm is working on numerous business development assignments to generate revenues, comprising signing new license deals and other strategic acquisitions to boost product development, distribution and production of newly manufactured or acquired hemp and cannabis based products.

Pin It on Pinterest